Cardinal Health reported steady revenue of $60.2 billion in the fourth quarter of fiscal 2025, essentially unchanged from the $59.9 billion recorded in the same period a year earlier. Adjusting for a previously announced customer contract expiration, revenue in the quarter rose by 21%.
The company’s profit measures showed robust growth in the quarter. Net income attributable to Cardinal Health increased modestly, while adjusted earnings — which exclude certain one-time items — grew by 20%. This was fueled by improved performance across its key business segments, including pharmaceutical distribution, specialty healthcare solutions, and medical products.
For the full fiscal year 2025, Cardinal Health’s revenue totaled $222.6 billion, down 2% from $226.8 billion in fiscal 2024. When excluding the impact of the contract expiration, revenue rose 18% over the year. Net income more than doubled to $1.6 billion from $852 million a year earlier.
The pharmaceutical and specialty solutions segment remained the company’s largest contributor, with revenue steady at $55.4 billion in the fourth quarter and a slight 3% decline to $204.6 billion for the full year. Segment profits improved thanks to growth in specialty and branded pharmaceutical sales and recent acquisitions.
The global medical products and distribution business saw a 3% revenue increase in the quarter, driven by higher volumes from existing customers. This segment’s profits rose sharply, nearly doubling compared to the same period last year.
The company’s “Ooher” segment, which includes home care supplies, nuclear and precision health services, and logistics, delivered the strongest growth with a 37% increase in fourth-quarter revenue and a 19% rise for the full year.
Looking ahead, Cardinal Health raised its profit guidance for fiscal 2026, expecting continued double-digit growth in its pharmaceutical and specialty solutions segment, steady gains in medical products, and accelerated growth in its other healthcare services.
In a strategic move to expand its specialty services, Cardinal Health announced plans to acquire Solaris Health, the nation’s largest urology medical service organization with more than 750 providers.
CEO Jason Hollar said, “Fiscal 2025 was a transformative year for Cardinal Health. Our strong results across all segments demonstrate disciplined execution and the impact of our growth initiatives. We enter fiscal 2026 with confidence in our momentum and future potential.”
In addition to the acquisition, the company highlighted several initiatives to support independent pharmacies and enhance patient care. These include a new advocacy program providing financial support to state pharmacy associations and the launch of an advanced patient monitoring system designed for continuous tracking of vital signs.
Cardinal Health also expanded its Equity Rx program, increasing access to affordable medications in multiple states and reinforcing its commitment to community health.
Don’t miss any content from Distribution Strategy Group. Join our list.
